FDA Senolytics Trials in 2026
As of 2026, the FDA is closely monitoring senolytics in clinical trials focused on aging and degenerative conditions. Fisetin and quercetin continue to be evaluated for their ability to clear senescent cells.
Clinical Landscape
Early results suggest potential benefits, but these compounds remain investigational. Researchers are assessing safety and long-term outcomes.
Official Insight
The U.S. Food and Drug Administration offers updates on ongoing senolytics trials and regulatory progress.
Strategic Data Expansion 2026.4
The FDA’s CBER division has granted 'Fast Track' status to several senolytic candidates in 2026 specifically targeting diabetic kidney disease and idiopathic pulmonary fibrosis. These trials are unique because they measure 'biomarkers of senescence' in blood and tissue samples to prove biological effect. The agency is particularly concerned with potential off-target effects, such as delayed wound healing, since senescent cells do play a limited role in tissue repair. This underscores the importance of the intermittent 'pulse' dosing schedules currently being tested to maximize benefits while minimizing side effects.